Comment on "Daratumumab, lenalidomide, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma: A real-world propensity score-matched study" [0.03%]
达雷木单抗、来那度胺和地塞米松与达雷木单抗、硼替佐米和地塞米松治疗复发/难治多发性骨髓瘤的现实世界倾向性匹配研究述评
Shobana Chandrasekar,M K Rohith Krishnan,Umesh Kumar
Shobana Chandrasekar
Comment on "Lifestyle modifications and non-pharmacological management in elderly hypertension" [0.03%]
关于“老年人高血压的生活方式改变和非药物治疗”
Mohd Aadam Bin Najeeb,V K Manjunatha,A P Cardiliya
Mohd Aadam Bin Najeeb
Comment on "Prevention and management of cytomegalovirus infection and disease in kidney transplant: A consensus statement of the Transplantation Society of Taiwan" [0.03%]
对台湾器官移植学会“肾脏移植巨细胞病毒感染和疾病的预防与处理共识声明”的评论
Swati Saxena,Ashish Mishra,Bhavna Sharma
Swati Saxena
Comment on "Automated liver volumetry and hepatic steatosis quantification with magnetic resonance imaging proton density fat fraction" [0.03%]
有关“利用磁共振成像质子密度脂肪分数进行自动化肝脏体积测量和肝脂肪变量化验”的评论
Vettri Vignesh Anand,Pavan Kumar Namdar,Krishna Prasanth Baalann
Vettri Vignesh Anand
Comment on "Hepatitis C micro-elimination in people who inject drugs: Incarcerated or methadone maintenance therapy in Taiwan" [0.03%]
对“台湾吸食毒品人群的丙型肝炎微消除：监禁还是美沙酮维持治疗？”一文的意见
S J Sarath Kumar,Shaffi Tangri,Pranshu Tangri
S J Sarath Kumar
Comment on "Machine learning-based prediction of CAC-defined cardiovascular risk using routine health examination data: a retrospective cross-sectional study in a Taiwanese population" [0.03%]
对“基于机器学习的使用常规健康检查数据定义冠状动脉钙化的台湾人群心血管风险预测研究”一文的评论
P S L Narasimharao Davuluri,Avinash Reddy Segireddy,Goutham Kumar Sheelam
P S L Narasimharao Davuluri